We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The majority of federal scientists investigated for improperly accepting personal money from drug companies or biotechnology firms escaped serious punishment, and investigators declined to proceed with several cases involving possible crimes, according to the National Institutes of Health.
Biopure Corporation announced that the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has validated the marketing authorization application (MAA) the company submitted on July 10, 2006 for Hemopure [hemoglobin glutamer -- 250 (bovine)] for the treatment of acutely anemic adult orthopedic surgery patients under 80 years of age.
The fate of the company's drug, Factive, is in the hands of the Anti-Infective Drug Advisory Committee, which is an advisory committee to the U.S. Food and Drug Administration.
Ariad Pharmaceuticals Inc., a developer of drugs to treat cancer, said Tuesday a federal court denied its motion to dismiss a lawsuit filed against it by biotechnology company Amgen Inc.
Bristol-Myers Squibb Co. on Tuesday ousted Peter R. Dolan as chief executive at the urging of a federal monitor, who found that the drug maker's patent deal with a generic competitor violated an agreement with prosecutors.
Skilled use of outsourcing can save drugmakers money, time and headaches, but it doesn't absolve them of ultimate responsibility for their product and data, a former FDA official said.
Generic drugmaker Synthon will have to wait until September 2007 to market a version of Pfizer's hypertension drug Norvasc unless it successfully appeals a recent ruling by North Carolina's Middle District court.
A bipartisan Senate coalition is trying to expand criminal penalties for violence against researchers and businesses involved with animal studies in an effort to stem an increase in such acts, which lawmakers say undermine medical innovation.
Inex Pharmaceuticals Corporation announced that it has become aware of a statement of claim filed by Protiva Biotherapeutics Inc. ("Protiva") in California Superior Court.